Adverse effects are a significant issue in the treatment of both cytotoxic drugs and newer targeted therapies, leading to dose reductions, dose delays, and treatment discontinuation.
Toxicity can reduce quality of life, jeopardies treatment adherence, and necessitate dose reductions and dose delays, all of which can have a negative impact on treatment response and outcome.
2. Learning Objectives:
After completing the lecture, students will be able to:
• Describe, and compare the adverse effects of cancer-
treatment drugs
3. Adverse effects are a significant issue in the treatment of both
cytotoxic drugs and newer targeted therapies, leading to dose
reductions, dose delays, and treatment discontinuation.
Toxicity can reduce quality of life, jeopardies treatment adherence,
and necessitate dose reductions and dose delays, all of which can
have a negative impact on treatment response and outcome.
4. • Cancer is a cell disease characterized by uncontrolled
tissue proliferation that is progressive, persistent, and
purposeless.
• Both normal and cancerous cells must go through the cell
cycle phases.
5. ALKYLATING AGENTS:
Adverse Effects:
• Dose-related (Nausea and vomiting)
• Occur primarily in:-
• Bone Marrow (Myelosuppression)
• GIT (Diarrhea)
• Reproductive system.
• Potent vesicants (blistering)
• Tissues damage at the site of administration
• Produce systemic toxicity.
6. • Carcinogenic in nature  increased risk of
secondary malignancies (Acute Myelogenous
Leukemia).
7. Alkylating Agents Acute Toxicity Delayed Toxicity
Mechlorethamine
Nausea and vomiting
• Severe bone marrow depression
• Alopecia and hemorrhagic cystitis (Cyclophosphamide).
• Skin pigmentation, pulmonary fibrosis, and adrenal insufficiency
(Busulfan)
Chlorambucil
Cyclophosphamide
Carmustine • Myelosuppression
• Rarely interstitial lung disease and interstitial nephritis
Lomustine
Altretamine • Myelosuppression, Peripheral neuropathy, Flu-like syndrome
Temozolomide Nausea and vomiting, headache
and fatigue
Myelosuppression, mild elevation in liver function tests, photosensitivity
Procarbazine CNS Depression Myelosuppression, hypersensitivity Reactions
Dacarbazine
Nausea and vomiting
Myelosuppression, CNS toxicity with neuropathy, Ataxia, Lethargy, &
Confusion
Cisplatin Nephrotoxicity, peripheral sensory neuropathy, ototoxicity,
nerve dysfunction
Carboplatin Myelosuppression; Rarely peripheral neuropathy, Renal toxicity, Hepatic
Dysfunction
Oxaliplatin
Nausea and vomiting,
Laryngopharyngeal Dysesthesias
Myelosuppression, peripheral sensory neuropathy, diarrhea
Toxicities (Alkylating Agents & Platinum Analogs)
8. NONCLASSIC ALKYLATINGAGENTS:
Procarbazine:
• Increased risk of secondary cancers (Acute Leukemia)
• Its carcinogenic potential is higher than alkylatingagents.
Dacarbazine:
• Dose-limiting toxicity (Myelosuppression)
• Severe nausea and vomiting
• A potent vesicant
Bendamustine:
• Dose-limiting toxicities (myelosuppression)
• Mild nausea & vomiting
• Hypersensitivity infusion reactions
• Skin rash